Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1994-4-18
|
| pubmed:abstractText |
Drug resistance conferred by specific human immunodeficiency virus type 1 (HIV-1) pol gene mutations has been associated with clinical progression in HIV-infected patients receiving anti-retroviral therapy. This study examined drug susceptibilities and pol mutations of HIV-1 strains from patients treated for 1 year with zidovudine, didanosine (ddI), or zidovudine and ddI. Ten (42%) of 24 patients receiving combination therapy versus 8/26 (31%) receiving only zidovudine had HIV-1 strains with phenotypic zidovudine resistance or a zidovudine resistance pol mutation at codon 215 (P = .6). In contrast, a ddI resistance mutation at codon 74 was less common among patients receiving combination therapy (2/24) than among those receiving ddI only (17/26; P < .001). Two patients receiving combination therapy developed resistance to zidovudine and ddI; they had HIV strains with amino acid mutations at codons 62, 75, 77, 116, and 151. Combination therapy with zidovudine and ddI selects for zidovudine-resistant HIV-1 strains lacking a ddI resistance mutation and for multidrug-resistant strains containing novel pol mutations.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amino Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Codon,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Primers,
http://linkedlifedata.com/resource/pubmed/chemical/Didanosine,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0022-1899
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
169
|
| pubmed:geneSymbol |
pol
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
722-9
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:8133086-Amino Acids,
pubmed-meshheading:8133086-Base Sequence,
pubmed-meshheading:8133086-Cells, Cultured,
pubmed-meshheading:8133086-Codon,
pubmed-meshheading:8133086-DNA, Viral,
pubmed-meshheading:8133086-DNA Primers,
pubmed-meshheading:8133086-Didanosine,
pubmed-meshheading:8133086-Drug Resistance, Microbial,
pubmed-meshheading:8133086-Drug Therapy, Combination,
pubmed-meshheading:8133086-Genes, pol,
pubmed-meshheading:8133086-HIV Seropositivity,
pubmed-meshheading:8133086-HIV-1,
pubmed-meshheading:8133086-Humans,
pubmed-meshheading:8133086-Molecular Sequence Data,
pubmed-meshheading:8133086-Mutation,
pubmed-meshheading:8133086-Polymerase Chain Reaction,
pubmed-meshheading:8133086-Proviruses,
pubmed-meshheading:8133086-RNA, Viral,
pubmed-meshheading:8133086-Zidovudine
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
|
| pubmed:affiliation |
Stanford University Medical Center, CA 94305.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|